19 citations
,
October 2013 in “Headache: The Journal of Head and Face Pain” The document concludes that inhalation of oxygen and sumatriptan injections are primary for cluster headaches, indomethacin for paroxysmal hemicrania, and lidocaine and lamotrigine for SUNCT, but SUNCT often resists treatment.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.
38 citations
,
January 2023 in “International Journal of Medical Sciences” Red-light therapy may slow myopia progression better than traditional treatments.
198 citations
,
September 2007 in “Clinics in Dermatology” Radiofrequency devices effectively tighten skin without surgery.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
9 citations
,
January 2012 in “International journal of trichology” Trichostasis spinulosa can be diagnosed with a simple skin biopsy and treated with specific gels, but lesions may return after stopping treatment.
February 2019 in “International journal of research in dermatology” The combined treatments were highly effective for improving atrophic acne scars.
135 citations
,
May 2002 in “Anesthesiology” CRPS type I is a complex pain condition with no proven cure, requiring personalized treatment.
1 citations
,
May 2025 in “Frontiers in Medicine” Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.
9 citations
,
November 2023 in “Pain Physician” ExoFlo is safe and effective for treating Complex Regional Pain Syndrome symptoms.
28 citations
,
August 1981 in “Journal of the American Academy of Dermatology” Retinoic acid is effective for treating eruptive vellus hair cysts.
3 citations
,
September 2024 in “Dermatology and Therapy” Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
November 2023 in “Frontiers in pharmacology” Drug repositioning offers hope for new, affordable treatments for a genetic skin disorder called ARCI.
11 citations
,
March 2024 in “Cell and Tissue Research” Telocytes have potential in therapy and tissue regeneration, but challenges in identification and cultivation remain.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
Raptor and Rictor have stable expression in hair cycles, with Raptor marking stem cells and Rictor involved in hair shaft formation.
4 citations
,
July 2024 in “Indian Dermatology Online Journal” ICMR created standard treatment guidelines for skin diseases to improve care across India.
December 2025 in “Frontiers in Medicine” Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
51 citations
,
September 2013 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” FRMS is a safe and effective treatment for acne scars in Asians with minimal side effects.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
6 citations
,
September 2023 in “Medicine” Nonpharmaceutical Traditional Chinese Medicine therapies for rheumatoid arthritis have been increasingly researched over the past 20 years.
37 citations
,
January 2023 in “Ophthalmology and Therapy” Low-level red light therapy can shorten eye length in some myopic children.
48 citations
,
May 2019 in “Genome Biology” Researchers found that certain RNA circles in the brain are linked to disease risk, but their exact role in disease is still unknown.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
March 2026 in “Journal for ImmunoTherapy of Cancer” Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.
April 2026 in “Clinical Cosmetic and Investigational Dermatology” Renal transplant recipients often have skin issues, especially infections, and need regular skin check-ups.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.